Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
47 hedge funds and large institutions have $202M invested in Galera Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 17 closing their positions.
20% more capital invested
Capital invested by funds: $168M → $202M (+$33.1M)
13% less funds holding
Funds holding: 54 → 47 (-7)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$9.02M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.19M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$2.07M |
| 4 |
ACM
Altium Capital Management
New York
|
+$1.79M |
| 5 |
Millennium Management
New York
|
+$963K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.3M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.85M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$2.41M |
| 4 |
State Street
Boston,
Massachusetts
|
-$910K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$651K |
GRTX Hedge Fund Activity: Q2 2021 in Review
47 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q2 2021, worth a combined $202M — up 20% from $168M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of GRTX and 10 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was AIGH Capital Management, adding an estimated $9.02M. The largest seller was BlackRock, cutting an estimated $3.3M.
- 47 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q2 2021, down from 54 in Q1 2021.
- Funds reported $202M of Galera Therapeutics, Inc. Common Stock stock for Q2 2021, up 20% quarter-over-quarter.
- 10 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q2 2021 and 17 closed out, a net change of -7 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q2 2021 was AIGH Capital Management, an estimated $9.02M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $3.3M sold.
Based on aggregated 13F filings for Q2 2021.